Jacobs Bruce N. 4
4 · Kymera Therapeutics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) CFO Bruce Jacobs Exercises Options and Sells Shares
What Happened
- Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics (KYMR), exercised stock options to acquire 61,378 shares at $5.33 per share (total cost ~$327,145). On the same day (2026-06-30) he sold approximately 77,109 shares in multiple open‑market transactions for aggregate proceeds of about $8.86 million. The filing also shows a disposition of 61,378 derivative shares at $0.00, consistent with a net/cashless settlement related to the option exercise.
Key Details
- Transaction date: 2026-06-30; Form 4 filed 2026-07-02 (timely).
- Option exercise: 61,378 shares acquired at $5.33 each (total ~$327,145).
- Open‑market sales: ~77,109 shares sold in multiple trades; total proceeds ≈ $8,864,829. Individual sale price ranges are noted in footnotes (roughly $110.37 to $118.09 depending on the lot; one weighted average range $117.55–$118.09).
- Notable footnotes: trades were effected under a Rule 10b5‑1 trading plan dated March 23, 2026 (F1); shares underlying the option were fully vested (F11); reported share counts include 373 ESPP shares (F2).
- Shares owned after the transactions: the excerpt provided does not list a total post‑transaction beneficial ownership number; the filing notes the reported count includes 373 ESPP shares.
Context
- This is a common insider pattern: exercising vested options and selling shares, much of it executed under a pre-established 10b5‑1 plan (reducing concerns about timing). The zero‑dollar derivative disposition indicates a net or cashless aspect of the option exercise (shares used to satisfy option exercise/withholding). These are routine executive liquidity events; purchases generally carry more interpretive weight than sales.
Insider Transaction Report
Form 4
Jacobs Bruce N.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-06-30$5.33/sh+61,378$327,145→ 321,992 total - Sale
Common Stock
[F1][F3]2026-06-30$110.54/sh−1,500$165,810→ 320,492 total - Sale
Common Stock
[F1][F4]2026-06-30$111.57/sh−1,700$189,664→ 318,792 total - Sale
Common Stock
[F1][F5]2026-06-30$112.79/sh−1,100$124,067→ 317,692 total - Sale
Common Stock
[F1][F6]2026-06-30$114.19/sh−4,110$469,311→ 313,582 total - Sale
Common Stock
[F1][F7]2026-06-30$114.77/sh−51,375$5,896,288→ 262,207 total - Sale
Common Stock
[F1][F8]2026-06-30$115.82/sh−7,971$923,178→ 254,236 total - Sale
Common Stock
[F1][F9]2026-06-30$116.99/sh−6,153$719,862→ 248,083 total - Sale
Common Stock
[F1][F10]2026-06-30$117.70/sh−3,200$376,649→ 244,883 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F11]2026-06-30−61,378→ 0 totalExercise: $5.33Exp: 2030-05-13→ Common Stock (61,378 underlying)
Footnotes (11)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]The shares underlying this stock option are fully vested and exercisable.
- [F2]This number includes 373 shares acquired under the Registrant's employee stock purchase plan.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Bruce N. Jacobs|2026-07-02